Sol-gel Technologies Ltd (SLGL)

$0.9

+0.03

(+3.45%)

Live

Insights on Sol-gel Technologies Ltd

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 213.0K → 466.0K (in $), with an average increase of 28.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -4.83M → -6.34M (in $), with an average decrease of 31.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.2% return, outperforming this stock by 146.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 242.2% return, outperforming this stock by 334.9%

Performance

  • $0.82
    $0.90
    $0.90
    downward going graph

    8.78%

    Downside

    Day's Volatility :8.78%

    Upside

    0.0%

    downward going graph
  • $0.63
    $4.05
    $0.90
    downward going graph

    29.88%

    Downside

    52 Weeks Volatility :84.42%

    Upside

    77.78%

    downward going graph

Returns

PeriodSol-gel Technologies LtdSector (Health Care)Index (Russel 2000)
3 Months
-15.56%
0.3%
0.0%
6 Months
-30.42%
9.9%
0.0%
1 Year
-72.21%
10.9%
0.0%
3 Years
-92.72%
17.9%
-20.9%

Highlights

Market Capitalization
24.2M
Book Value
$1.17
Earnings Per Share (EPS)
-0.81
Wall Street Target Price
6.0
Profit Margin
0.0%
Operating Margin TTM
-1440.34%
Return On Assets TTM
-35.07%
Return On Equity TTM
-59.6%
Revenue TTM
1.7M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-38.5%
Gross Profit TTM
-8.8M
EBITDA
-24.7M
Diluted Eps TTM
-0.81
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.83
EPS Estimate Next Year
-0.5
EPS Estimate Current Quarter
-0.15
EPS Estimate Next Quarter
-0.18

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Sol-gel Technologies Ltd(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 566.67%

Current $0.90
Target $6.00

Company Financials

FY18Y/Y Change
Revenue
129.0K
↓ 25.86%
Net Income
-32.2M
↑ 2.01%
Net Profit Margin
-25.0K%
↓ 6821.04%
FY19Y/Y Change
Revenue
22.9M
↑ 17655.04%
Net Income
-24.6M
↓ 23.58%
Net Profit Margin
-107.44%
↑ 24856.13%
FY20Y/Y Change
Revenue
8.8M
↓ 61.71%
Net Income
-27.4M
↑ 11.35%
Net Profit Margin
-312.4%
↓ 204.96%
FY21Y/Y Change
Revenue
31.3M
↑ 256.54%
Net Income
4.4M
↓ 115.9%
Net Profit Margin
13.94%
↑ 326.34%
FY22Y/Y Change
Revenue
3.9M
↓ 87.58%
Net Income
-13.6M
↓ 412.12%
Net Profit Margin
-350.3%
↓ 364.24%
FY23Y/Y Change
Revenue
1.6M
↓ 59.98%
Net Income
-27.2M
↑ 100.25%
Net Profit Margin
-1.8K%
↓ 1402.47%
Q4 FY22Q/Q Change
Revenue
100.0K
↓ 61.69%
Net Income
-4.9M
↑ 66.44%
Net Profit Margin
-4.9K%
↓ 3806.69%
Q1 FY23Q/Q Change
Revenue
758.0K
↑ 658.0%
Net Income
-31.1M
↑ 529.54%
Net Profit Margin
-4.1K%
↑ 838.01%
Q2 FY23Q/Q Change
Revenue
594.0K
↓ 21.64%
Net Income
-6.0M
↓ 80.82%
Net Profit Margin
-1.0K%
↑ 3101.94%
Q3 FY23Q/Q Change
Revenue
213.0K
↓ 64.14%
Net Income
-5.7M
↓ 4.34%
Net Profit Margin
-2.7K%
↓ 1676.17%
Q4 FY23Q/Q Change
Revenue
447.0K
↑ 109.86%
Net Income
-4.8M
↓ 15.32%
Net Profit Margin
-1.1K%
↑ 1599.34%
Q1 FY24Q/Q Change
Revenue
466.0K
↑ 4.25%
Net Income
-6.3M
↑ 31.18%
Net Profit Margin
-1.4K%
↓ 279.49%
FY18Y/Y Change
Total Assets
69.7M
↑ 354.99%
Total Liabilities
5.8M
↓ 91.51%
FY19Y/Y Change
Total Assets
61.3M
↓ 12.03%
Total Liabilities
8.8M
↑ 53.06%
FY20Y/Y Change
Total Assets
59.2M
↓ 3.49%
Total Liabilities
8.3M
↓ 5.93%
FY21Y/Y Change
Total Assets
69.2M
↑ 16.95%
Total Liabilities
13.6M
↑ 63.56%
FY22Y/Y Change
Total Assets
46.6M
↓ 32.61%
Total Liabilities
4.4M
↓ 67.52%
FY23Y/Y Change
Total Assets
45.3M
↓ 2.88%
Total Liabilities
6.6M
↑ 50.46%
Q4 FY22Q/Q Change
Total Assets
46.6M
↓ 9.09%
Total Liabilities
4.4M
↑ 15.76%
Q1 FY23Q/Q Change
Total Assets
49.0M
↑ 5.18%
Total Liabilities
5.0M
↑ 12.82%
Q2 FY23Q/Q Change
Total Assets
55.1M
↑ 12.36%
Total Liabilities
6.8M
↑ 36.66%
Q3 FY23Q/Q Change
Total Assets
49.9M
↓ 9.51%
Total Liabilities
6.7M
↓ 1.04%
Q4 FY23Q/Q Change
Total Assets
45.3M
↓ 9.18%
Total Liabilities
6.6M
↓ 1.38%
Q1 FY24Q/Q Change
Total Assets
39.9M
↓ 11.87%
Total Liabilities
7.3M
↑ 9.29%
FY18Y/Y Change
Operating Cash Flow
-23.5M
↓ 2.58%
Investing Cash Flow
-54.7M
↑ 821.78%
Financing Cash Flow
78.8M
↑ 181.5%
FY19Y/Y Change
Operating Cash Flow
-22.5M
↓ 4.12%
Investing Cash Flow
16.0M
↓ 129.28%
Financing Cash Flow
10.6M
↓ 86.53%
FY20Y/Y Change
Operating Cash Flow
-25.2M
↑ 12.18%
Investing Cash Flow
-2.7M
↓ 116.81%
Financing Cash Flow
26.5M
↑ 149.29%
FY21Y/Y Change
Operating Cash Flow
-7.7M
↓ 69.53%
Investing Cash Flow
19.9M
↓ 837.64%
Financing Cash Flow
837.0K
↓ 96.84%
FY22Y/Y Change
Operating Cash Flow
-9.5M
↑ 23.31%
Investing Cash Flow
1.7M
↓ 91.45%
Financing Cash Flow
15.0K
↓ 98.21%
Q2 FY19Q/Q Change
Operating Cash Flow
-4.5M
↑ 59.1%
Investing Cash Flow
21.9M
↓ 140.07%
Financing Cash Flow
-78.8M
↑ 55.1%
Q4 FY19Q/Q Change
Operating Cash Flow
-9.7M
↑ 113.06%
Investing Cash Flow
16.0M
↓ 26.95%
Financing Cash Flow
10.6M
↓ 113.46%

Technicals Summary

Sell

Neutral

Buy

Sol-gel Technologies Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sol-gel Technologies Ltd
Sol-gel Technologies Ltd
23.36%
-30.42%
-72.21%
-92.72%
-90.46%
Moderna, Inc.
Moderna, Inc.
-5.49%
54.62%
7.28%
-36.0%
777.93%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.25%
23.44%
33.01%
94.49%
224.24%
Novo Nordisk A/s
Novo Nordisk A/s
5.94%
38.98%
74.18%
240.71%
450.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.8%
16.75%
36.36%
148.95%
156.51%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sol-gel Technologies Ltd
Sol-gel Technologies Ltd
18.42
NA
NA
-0.83
-0.6
-0.35
NA
1.17
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.68
30.68
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.23
49.23
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.3
30.3
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sol-gel Technologies Ltd
Sol-gel Technologies Ltd
Buy
$24.2M
-90.46%
18.42
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.1B
777.93%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.5B
224.24%
30.68
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$629.2B
450.86%
49.23
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.6B
156.51%
30.3
39.46%

Institutional Holdings

  • Phoenix Holdings Ltd

    9.24%
  • Armistice Capital, LLC

    7.46%
  • Migdal Insurance & Financial Holdings Ltd

    4.41%
  • Harel Insurance Invests & Fin Srvcs Ltd

    3.30%
  • Kingdon Capital Management LLC

    1.73%
  • Yelin Lapidot Holdings Management Ltd

    0.82%

Company Information

sol-gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. our lead product candidates, vered for the treatment of papulopustular rosacea and twin and sirs-t for the treatment of acne vulgaris (“acne”) are based upon our proprietary microencapsulation delivery system. this technology consists of microcapsules made of silica. based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs. our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. this creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. our delivery system also enables to produce novel fixed-dose combinations th

Organization
Sol-gel Technologies Ltd
Employees
36
CEO
Dr. Alon Seri-Levy
Industry
Health Technology

FAQs